eligibility_summary
Adults (≥18) with relapsed/refractory NHL (DLBCL incl HGBL with MYC/BCL2 and FL) after ≥2 prior lines (post-transformation for tDLBCL, FL per treatment criteria), with measurable FDG-avid disease ≥1.5 cm, agree to contraception. Exclude ECOG ≥2, noncompliance, prior CAR-T, recent RT/systemic therapy, SCT limits (allo ≤6 mo, auto ≤3 mo), TCE combos: no prior allo/solid organ Tx, PML, HLH, chronic EBV, serious illness/infection, CNS involvement.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study tests BMS-986458 alone or with anti-lymphoma agents in R/R NHL (DLBCL, FL). BMS-986458: small-molecule, bifunctional cereblon-dependent targeted protein degrader (TPD/PROTAC) that recruits the CRBN E3 ligase to ubiquitinate and proteasomally degrade BCL6, suppressing BCL6-driven transcriptional programs in germinal center B-cell lymphomas. Combinations: rituximab (chimeric anti-CD20 mAb, B-cell depletion via CDC, ADCC/ADCP, apoptosis), glofitamab with obinutuzumab pre-dose (CD20×CD3 bispecific T-cell engager plus glycoengineered type II anti-CD20 mAb), mosunetuzumab (CD20×CD3 bispecific). Targets/pathways: malignant CD20+ B cells, BCL6 pathway, CRBN–ubiquitin–proteasome system, T-cell (CD3) engagement.